US Top News and Analysis29d ago
Cholesterol drug setback casts doubt over multibillion-dollar raceAInegative
Novartis reported a setback for its cholesterol drug, casting doubt on the broader effort to lower Lp(a) levels and reduce cardiovascular events. The development raises concerns for rivals Amgen and Eli Lilly, who are also pursuing treatments in this space.
Impact: The news may weigh on Amgen (AMGN) and Eli Lilly (LLY) shares as investors reassess the timeline and potential market for Lp(a)-lowering therapies.
Not investment advice